While imatinib caused a statistically significant reduction in glucose incorporation in CML CD34+CD38− cells, the relative PC/PDH activity increased in all three patient samples in this primitive population with a trend towards statistical significance (Fig. 3h, p-value = 0.0870). This evidence concerns the gene PDP1 and chronic myelogenous leukemia, BCR-ABL1 positive.